Adalimumab-aaty - Biologic Drug Details

Summary for adalimumab-aaty

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for adalimumab-aaty Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for adalimumab-aaty Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for adalimumab-aaty Derived from Patent Text Search

No patents found based on company disclosures

Last updated: February 20, 2026

Market Dynamics and Financial Trajectory for Adalimumab-aaty

Adalimumab-aaty, marketed as Idacio, is a biosimilar to the originator biologic Humira (adalimumab). It targets autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Market Entry and Approval Timeline

• Initial Approval: Idacio received FDA approval in June 2019 and EMA approval in November 2019.
• Indications: Approved for the same indications as Humira, including immune-mediated inflammatory diseases.
• Launch Countries: Launched in the U.S., Europe, and Japan; available in multiple additional markets.

Market Share and Competition

Year	U.S. Biosimilar Market Share (%)	Key Competitors	Biosimilar Launches
2019	< 5	Amjevita (Amgen), Imraldi (Amgen), Hadlima (Sandoz)	Multiple launched post-2018
2020	10	Additional biosimilars introduced	Continued market entry development
2021	20	Increasing competition impacts revenue	Several biosimilar launches in the EU and US
2022	30+	Market consolidation begins	Firm market presence established

Pricing and Reimbursement Trends

• Pricing: Biosimilars underprice the originator by 15–30% initially, with discounts increasing over time.
• Reimbursement: Payer policies favor biosimilars, leading to accelerated substitution in clinics.
• Market Penetration: Increased uptake correlates with cost savings for healthcare systems, leading to higher adoption rates.

Revenue Directions and Forecasts

Year	Estimated Revenue (USD billion)	Notes
2019	0.2 (initial launch year)	Limited uptake
2020	0.5	Rapid adoption in key markets
2021	1.0	Continued growth, increased formulary inclusion
2022	1.5+	Market stabilizes, competitor entries moderate growth

Projection models estimate that Idacio could reach USD 2 billion in annual revenues by 2025, contingent on biosimilar market penetration and volume growth.

Drivers of Market Growth

• Cost Savings: Biosimilars reduce treatment costs by approximately 20–30%.
• Policy Support: Governments push biosimilar use to curb healthcare spending.
• Physician Adoption: Increased confidence in biosimilarity and regulatory standards.
• Patient Access: Greater accessibility due to lower prices.

Challenges

• Patent Litigation: Ongoing patent protections around Humira delayed biosimilar entry in the U.S. until 2023.
• Physician Perception: Hesitancy persists among some clinicians regarding biosimilar interchangeability.
• Market Saturation: Multiple biosimilars target Humira, pushing prices down further.

Key Takeaways

• Idacio entered a highly competitive biosimilar market with significant growth potential.
• Revenue ramp-up is driven by declining drug prices and policy incentives.
• Market share in the US remains limited compared to the global stage but is expected to grow with increased adoption.
• Competition from other biosimilars dampens margins but drives overall market expansion.
• Long-term growth hinges on overcoming patent barriers and fostering physician trust.

FAQs

1. When did Idacio gain FDA approval?
June 2019.

2. What diseases does Idacio treat?
Rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and other autoimmune conditions.

3. How does Idacio price compare with Humira?
Biosimilars typically sell at 15–30% lower prices initially, with discounts increasing over time.

4. What is the primary marketing challenge for Idacio?
Overcoming physician hesitancy and patent litigation delays.

5. What is the forecasted revenue for Idacio in 2025?
Approximately USD 2 billion, assuming market dynamics remain stable.

---

References

1. U.S. Food and Drug Administration. (2019). FDA approves Idacio, a biosimilar to Humira. https://www.fda.gov/news-events/press-announcements/fda-approves-idacio-biosimilar-humira
2. European Medicines Agency. (2019). EMA validates Idacio for distribution. https://www.ema.europa.eu/en/news/ema-validates-idacio-application
3. IQVIA. (2022). Global biologics market report.
4. EvaluatePharma. (2022). Biologics market forecasts.